These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8088061)

  • 21. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis.
    Carette S; Calin A; McCafferty JP; Wallin BA
    Arthritis Rheum; 1989 Feb; 32(2):158-65. PubMed ID: 2645874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic gold therapy.
    Papp KA; Shear NH
    Clin Dermatol; 1991; 9(4):535-51. PubMed ID: 1822410
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative safety and efficacy of auranofin and parenteral gold compounds: a review.
    Horton RJ
    Scand J Rheumatol Suppl; 1983; 51():100-10. PubMed ID: 6426044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis.
    Davis P; Menard H; Thompson J; Harth M; Beaudet F
    J Rheumatol; 1985 Feb; 12(1):60-7. PubMed ID: 3920393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.
    Capell HA; Lewis D; Carey J
    Ann Rheum Dis; 1986 Sep; 45(9):705-11. PubMed ID: 3094463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report.
    Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K
    J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gold concentrations and toxicity during oral gold treatment with auranofin.
    Sharma RP; Smillie J; Palmer DG
    Pharmacology; 1985; 30(2):115-20. PubMed ID: 3919401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scarring alopecia following gold therapy.
    Burrows NP; Grant JW; Crisp AJ; Roberts SO
    Acta Derm Venereol; 1994 Nov; 74(6):486. PubMed ID: 7701895
    [No Abstract]   [Full Text] [Related]  

  • 29. Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials.
    Dahl SL; Samuelson CO; Williams HJ; Ward JR; Karg M
    Pharmacotherapy; 1990; 10(2):79-84. PubMed ID: 2112243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.
    Jessop JD; O'Sullivan MM; Lewis PA; Williams LA; Camilleri JP; Plant MJ; Coles EC
    Br J Rheumatol; 1998 Sep; 37(9):992-1002. PubMed ID: 9783766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open comparative study of auranofin vs. gold sodium thiomalate.
    Smith PR; Brown GM; Meyers OL
    J Rheumatol Suppl; 1982; 8():190-6. PubMed ID: 6813484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of auranofin: a review of clinical experience.
    Blodgett RC; Pietrusko RG
    Scand J Rheumatol Suppl; 1986; 63():67-78. PubMed ID: 3110943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical response to auranofin in patients with psoriatic arthritis.
    Salvarani C; Zizzi F; Macchioni P; Mantovani W; Rossi F; Baricchi R; Bellelli A; Capozzoli N; Frizziero L; Portioli I
    Clin Rheumatol; 1989 Mar; 8(1):54-7. PubMed ID: 2743720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythrocyte membrane gold levels after treatment with auranofin and sodium aurothiomalate.
    Iqbal MS; Saeed M; Taqi SG
    Biol Trace Elem Res; 2008; 126(1-3):56-64. PubMed ID: 18649049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis.
    Dequeker J; Gevers G
    Scand J Rheumatol Suppl; 1986; 63():85-95. PubMed ID: 3474779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 6. Bucillamine and gold (gold sodium thiomalate and auranofin)].
    Ito S
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2936-41. PubMed ID: 22175134
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis.
    Furst DE
    Pharmacotherapy; 1983; 3(5):284-98. PubMed ID: 6417628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
    Chaffman M; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1984 May; 27(5):378-424. PubMed ID: 6426923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis.
    Dequeker J; Verdickt W; Gevers G; Vanschoubroek K
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():67-74. PubMed ID: 6432416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Gold compounds and D-penicillamine for therapy of rheumatoid arthritis].
    Miyamoto S; Inoue T
    Nihon Rinsho; 1992 Mar; 50(3):515-20. PubMed ID: 1588740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.